US 12,276,670 B2
Methods for identifying and treating adrenomyeloneuropathy (AMN)
Florian Eichler, Cambridge, MA (US); and Yi Gong, Malden, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Appl. No. 16/651,926
Filed by The General Hospital Corporation, Boston, MA (US)
PCT Filed Oct. 1, 2018, PCT No. PCT/US2018/053709
§ 371(c)(1), (2) Date Mar. 27, 2020,
PCT Pub. No. WO2019/068072, PCT Pub. Date Apr. 4, 2019.
Claims priority of provisional application 62/565,753, filed on Sep. 29, 2017.
Prior Publication US 2020/0309788 A1, Oct. 1, 2020
Int. Cl. G01N 33/68 (2006.01); C07K 16/04 (2006.01)
CPC G01N 33/6896 (2013.01) [C07K 16/04 (2013.01); G01N 33/6893 (2013.01); G01N 2800/52 (2013.01)] 9 Claims
 
1. A method, comprising:
providing a biological sample from a spine of a human male subject diagnosed with X-linked adrenoleukodystrophy (X-ALD), and
detecting a level of milk fat globule-EGF factor 8 (MFGE8), complement C1q A chain (C1qa), triggering receptor expressed on myeloid cells 2 (Trem2), or growth arrest specific 6 (Gas6), in the sample.